Supply shortages forced Novo Nordisk to restrict the availability of those lower doses in the U.S. since May. But why are those lower doses important? It's because people are supposed to start Wegovy at a low dose and gradually increase the size over time to mitigate side effects such as nausea. So, more of those low "starter" doses means more new patients can begin treatment with Wegovy. The company plans to "gradually" increase the overall supply of Wegovy throughout the rest of the year, executives added on the company's fourth-quarter earnings call Wednesday.